The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins
- 1 June 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Oral Investigations
- Vol. 7 (2), 108-112
- https://doi.org/10.1007/s00784-003-0200-0
Abstract
Regenerative treatment with enamel matrix proteins (EMD) has been shown to promote regeneration in intrabony periodontal defects. However, up to now various postoperative regimens such as the routine administration of nonsteroidal anti-inflammatory drugs (NSAIDs) were often used in combination with enamel matrix proteins. Therefore, it cannot be excluded that the results might have been influenced by the effect of the postoperative medication. The aim of this randomized, controlled, blinded, clinical investigation was to determine the effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony periodontal defects following regenerative periodontal surgery with EMD. Twenty two patients, each of whom exhibited one deep intrabony defect, were randomly treated with either EMD plus a selective cyclo-oxygenase-2 (COX-2) inhibitor (test) or with EMD alone (control). The postoperative regimen consisted of oral administration of 12.5 mg rofecoxib twice daily for 14 days. The following parameters were recorded at baseline and at 6 months by the same calibrated and blinded investigator: plaque index (Pl), gingival index (GI), bleeding on probing (BOP), pocket depth (PD), gingival recession (GR), and clinical attachment level (CAL). Power analysis to determine superiority of the anti-inflammatory treatment showed that the available sample size would yield 70% power to detect a 1 mm difference. No statistical significant differences in any of the investigated parameters between the two groups were observed at baseline. The results show that, in the test group, mean PD decreased from 8.7±1.4 mm to 4.7±2.0 mm (PPPP<0.001). There were no significant differences between the two groups in any of the investigated parameters. Within the limits of the present study, it can be concluded that the systemic administration of a selective COX-2 inhibitor following regenerative periodontal surgery with EMD did not result in additional clinical improvements when compared to treatment with EMD alone.Keywords
This publication has 16 references indexed in Scilit:
- Prevalence of aggressive periodontitis in school attendees in UgandaJournal of Clinical Periodontology, 2002
- Effect of Selective Cyclooxygenase‐2 Inhibition on the Development of Ligature‐Induced Periodontitis in RatsThe Journal of Periodontology, 2002
- Cyclooxygenase‐2 Is Upregulated in Inflamed Gingival TissuesThe Journal of Periodontology, 2001
- Selective Cyclooxygenase‐2 Inhibition Prevents Alveolar Bone Loss in Experimental Periodontitis in RatsThe Journal of Periodontology, 2000
- Histologic Evaluation of Periodontal Healing in Humans Following Regenerative Therapy With Enamel Matrix Derivative. A 10‐Case SeriesThe Journal of Periodontology, 2000
- Enamel Matrix‐Derived Protein Stimulates Attachment of Periodontal Ligament Fibroblasts and Enhances Alkaline Phosphatase Activity and Transforming Growth Factor β1 Release of Periodontal Ligament and Gingival FibroblastsThe Journal of Periodontology, 2000
- Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trialClinical Therapeutics, 1999
- Equivalence and Superiority Testing in Regeneration Clinical TrialsThe Journal of Periodontology, 1998
- Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects.Journal of Clinical Periodontology, 1997
- Altering the Progression of Human Alveolar Bone Loss With the Non‐Steroidal Anti‐Inflammatory Drug FlurbiprofenThe Journal of Periodontology, 1989